Top

BMC Medicine

Published in:

Open Access 01-12-2022 | Vaccination | Research article

An assessment of the vaccination of school-aged children in England against SARS-CoV-2

Authors: Matt J. Keeling, Sam E. Moore

Published in: BMC Medicine | Issue 1/2022

Abstract

Background

Children and young persons are known to have a high number of close interactions, often within the school environment, which can facilitate rapid spread of infection; yet for SARS-CoV-2, it is the elderly and vulnerable that suffer the greatest health burden. Vaccination, initially targeting the elderly and vulnerable before later expanding to the entire adult population, has been transformative in the control of SARS-CoV-2 in England. However, early concerns over adverse events and the lower risk associated with infection in younger individuals means that the expansion of the vaccine programme to those under 18 years of age needs to be rigorously and quantitatively assessed.

Methods

Here, using a bespoke mathematical model matched to case and hospital data for England, we consider the potential impact of vaccinating 12–17 and 5–11-year-olds. This analysis is reported from an early model (generated in June 2021) that formed part of the evidence base for the decisions in England, and a later model (from November 2021) that benefits from a richer understanding of vaccine efficacy, greater knowledge of the Delta variant wave and uses data on the rate of vaccine administration. For both models, we consider the population wide impact of childhood vaccination as well as the specific impact on the age groups targeted for vaccination.

Results

Projections from June suggested that an expansion of the vaccine programme to those 12–17 years old could generate substantial reductions in infection, hospital admission and deaths in the entire population, depending on population behaviour following the relaxation of control measures. The benefits within the 12–17-year-old cohort were less marked, saving between 660 and 1100 (95% PI (prediction interval) 280–2300) hospital admissions and between 22 and 38 (95% PI 9–91) deaths depending on assumed population behaviour. For the more recent model, the benefits within this age group are reduced, saving on average 630 (95% PI 300–1300) hospital admissions and 11 (95% PI 5–28) deaths for 80% vaccine uptake, while the benefits to the wider population represent a reduction of 8–10% in hospital admissions and deaths. The vaccination of 5–11-year-olds is projected to have a far smaller impact, in part due to the later roll-out of vaccines to this age group.

Conclusions

Vaccination of 12–170-year-olds and 5–11-year-olds is projected to generate a reduction in infection, hospital admission and deaths for both the age groups involved and the population in general. For any decision involving childhood vaccination, these benefits needs to be balanced against potential adverse events from the vaccine, the operational constraints on delivery and the potential for diverting resources from other public health campaigns.

Available only for authorised users

Brauner JM, Mindermann S, Sharma M, Johnston D, Salvatier J, Gavenciak T, Stephenson AB, Leech G, Altman G, Mikulik V, Norman AJ, Monrad JT, Besiroglu T, Ge H, Hartwick MA, Teh YW, Chindelevitch L, Gal Y, Kulveit J. Inferring the effectiveness of government interventions against COVID-19. Science. 2021; 371(6531):802. https://doi.org/10.1126/science.abd9338.CrossRef

Liu Y, Morgenstern C, Kelly J, Lowe R, Jit M, Grp CC-W. The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories. BMC Med. 2021;19(1). https://doi.org/10.1186/s12916-020-01872-8.

Sharma M, Mindermann S, Rogers-Smith C, Leech G, Snodin B, Ahuja J, Sandbrink JB, Monrad JT, Altman G, Dhaliwal G, Finnveden L, Norman AJ, Oehm SB, Sandkuehler JF, Aitchison L, Gavenciak T, Mellan T, Kulveit J, Chindelevitch L, Flaxman S, Gal Y, Mishra S, Bhatt S, Brauner JM. Understanding the effectiveness of government interventions against the resurgence of COVID-19 in Europe. Nat Commun. 2021;12(1). https://doi.org/10.1038/s41467-021-26013-4.

Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, Pearson CA, Russell TW, Tully DC, Washburne AD, et al.Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372(6538). https://doi.org/10.1126/science.abg3055.

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603–15. https://doi.org/10.1056/NEJMoa2034577.PubMedCrossRef

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, et al.Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021; 397(10269):99–111. https://doi.org/10.1016/S0140-6736(20)32661-1.PubMedPubMedCentralCrossRef

Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta K, Jones J, House T, VanSteenHouse H, Bell I, et al.Impact of vaccination on new SARS-CoV-2 infections in the UK. Nat Med. 2021. https://doi.org/10.1038/s41591-021-01410-w.

Moore S, Hill EM, Dyson L, Tildesley MJ, Keeling MJ. Modelling optimal vaccination strategy for SARS-CoV-2 in the UK. PLoS Comput Biol. 2021; 17(5):1008849. https://doi.org/10.1371/journal.pcbi.1008849.CrossRef

Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr Int J Paediatr. 2020; 109(March):1088–95. https://doi.org/10.1111/apa.15270.CrossRef

10.

Viner RM, Mytton OT, Bonell C, Melendez-Torres G, Ward J, Hudson L, Waddington C, Thomas J, Russell S, Van Der Klis F, et al.Susceptibility to sars-cov-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis. JAMA Pediatr. 2021; 175(2):143–56. https://doi.org/10.1001/jamapediatrics.2020.4573.PubMedCrossRef

11.

Barton M, Mehta K, Kumar K, Lu J, le Saux N, Sampson M, Robinson J. COVID- 19 Infection in Children: Estimating Pediatric Morbidity and Mortality. medRxiv. 2020;1–26. https://doi.org/10.1101/2020.05.05.20091751.

12.

Smith C, Odd D, Harwood R, Ward J, Linney M, Clark M, Hargreaves D, Ladhani SN, Draper E, Davis PJ, et al.Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year. Nat Med. 2021;1–8. https://doi.org/10.1038/s41591-021-01578-1.

13.

DELVE. Balancing the Risks of Pupils Returning to Schools. 2021. https://rs-delve.github.io/reports/2020/07/24/balancing-the-risk-of-pupils-returning-to-schools.html. Accessed 15 July 2021.

14.

Courtemanche C, Garuccio J, Le A, Pinkston J, Yelowitz A. Strong Social Distancing Measures In The United States Reduced The COVID-19 Growth Rate. Health Aff. 2020; 39:7. https://doi.org/10.1377/hlthaff.2020.00608.CrossRef

15.

Viner RM, Russell SJ, Croker H, Packer J, Ward J, Stansfield C, Mytton O, Bonell C, Booy R. School closure and management practices during coronavirus outbreaks including COVID-19: a rapid systematic review. Lancet Child Adolesc Heal. 2020; 4(5):397–404. https://doi.org/10.1016/S2352-4642(20)30095-X.CrossRef

16.

Koestner C, Letzel S, Eggert V, Beutel T, Dietz P. Comparing SARS-CoV-2 case rates between pupils, teachers and the general population: results from Ger-many. medRxiv. 2021. https://doi.org/10.1101/2021.03.04.21252877.

17.

Keeling MJ, Tildesley MJ, Atkins BD, Penman B, Southall E, Guyver-Fletcher G, Holmes A, McKimm H, Gorsich EE, Hill EM, et al.The impact of school reopening on the spread of COVID-19 in England. Phil Trans R Soc B. 2021; 376(1829):20200261. https://doi.org/10.1098/rstb.2020.0261.PubMedPubMedCentralCrossRef

18.

Munday JD, Sherratt K, Meakin S, Endo A, Pearson CAB, Hellewell J, Abbott S, Bosse NI, Atkins KE, Wallinga J, Edmunds WJ, van Hoek AJ, Funk S. Implications of the school-household network structure on SARS-CoV-2 transmission under school reopening strategies in England. Nat Commun. 2021; 12:1942. https://doi.org/10.1038/s41467-021-22213-0.PubMedPubMedCentralCrossRef

19.

Lessler J, Grabowski MK, Grantz KH, Badillo-Goicoechea E, Metcalf CJE, Lupton-Smith C, Azman AS, Stuart EA. Household covid-19 risk and in-person schooling. Science. 2021; 372(6546):1092–7.PubMedCrossRef

20.

Panovska-Griffiths J, Stuart RM, Kerr CC, Rosenfield K, Mistry D, Waites W, Klein DJ, Bonell C, Viner RM. Modelling the impact of reopening schools in the uk in early 2021 in the presence of the alpha variant and with roll-out of vaccination against sars-cov-2. J Math Anal Appl. 2022;126050. https://doi.org/10.1016/j.jmaa.2022.126050.

21.

Panovska-Griffiths J, Kerr CC, Stuart RM, Mistry D, Klein DJ, Viner RM, Bonell C. Determining the optimal strategy for reopening schools, the impact of test and trace interventions, and the risk of occurrence of a second COVID-19 epidemic wave in the UK: a modelling study. Lancet Child Adolesc Heal. 2020; 4(11):817–27. https://doi.org/10.1016/S2352-4642(20)30250-9.CrossRef

22.

Gandini S, Rainisio M, Iannuzzo ML, Bellerba F, Cecconi F, Scorrano L. No evidence of association between schools and SARS-CoV-2 second wave in Italy. medRxiv. 2020. https://doi.org/10.1101/2020.12.16.20248134.

23.

Di Domenico L, Pullano G, Sabbatini CE, Boëlle P-Y, Colizza V. Modelling safe protocols for reopening schools during the COVID-19 pandemic in France. Nat Commun. 2021; 12:1073. https://doi.org/10.1038/s41467-021-21249-6.PubMedPubMedCentralCrossRef

24.

Brooks-Pollock E, Read JM, McLean AR, Keeling MJ, Danon L. Mapping social distancing measures to the reproduction number for COVID-19. Phil Trans R Soc B. 2021;376(1829). https://doi.org/10.1098/rstb.2020.0276.

25.

Flasche S, Edmunds WJ. The role of schools and school-aged children in SARS-CoV-2 transmission. Lancet Infect Dis. 2021; 21(3):298–9. https://doi.org/10.1016/S1473-3099(20)30927-0.PubMedCrossRef

26.

Asgary A, Cojocaru MG, Najafabadi MM, Wu J. Simulating preventative testing of SARS-CoV-2 in schools: policy implications. BMC Public Health. 2021; 21(1):1–18. https://doi.org/10.1186/s12889-020-10153-1.CrossRef

27.

Rozhnova G, van Dorp CH, Bruijning-Verhagen P, Bootsma MC, van de Wijgert JH, Bonten MJ, Kretzschmar ME. Model-based evaluation of school-and non-school-related measures to control the COVID-19 pandemic. Nat Commun. 2021;12(1614). https://doi.org/10.1038/s41467-021-21899-6.

28.

McGee RS, Homburger JR, Williams HE, Bergstrom CT, Zhou AY. Model-driven mitigation measures for reopening schools during the covid-19 pandemic. Proc Natl Acad Sci. 2021; 118(39):2108909118. https://doi.org/10.1073/pnas.2108909118.CrossRef

29.

Woodhouse MJ, Aspinall WP, Sparks RSJ, Pollock EB, Relton C. Alternative Covid-19 mitigation measures in school classrooms: analysis using an agent-based model of SARS-CoV-2 transmission. medRxiv. 2022. https://doi.org/10.1101/2021.08.30.21262826.

30.

Wong BLH, Ramsay ME, Ladhani SN. Should children be vaccinated against covid-19 now?Arch Dis Child. 2021. https://doi.org/10.1136/archdischild-2020-321225.

31.

Zimmermann P, Pittet LF, Finn A, Pollard AJ, Curtis N. Should children be vaccinated against covid-19?Arch Dis Child. 2022; 107(3):1–1. https://doi.org/10.1136/archdischild-2021-323040.CrossRef

32.

Gurdasani D, Bhatt S, Costello A, Denaxas S, Flaxman S, Greenhalgh T, Griffin S, Hyde Z, Katzourakis A, McKee M, et al.Vaccinating adolescents against SARS-CoV-2 in England: a risk–benefit analysis. J R Soc Med. 2021; 114(11):513–24. https://doi.org/10.1177/01410768211052589.PubMedPubMedCentralCrossRef

33.

Ladhani SN, sKIDs Investigation Team. Children and covid-19 in schools. Science. 2021; 374(6568):680–2. https://doi.org/10.1126/science.abj2042.PubMedCrossRef

34.

Viner RM, Mytton OT, Bonell C, Melendez-Torres GJ, Ward JL, Hudson L, Waddington C, Thomas J, Russell S, Klis F. v. d., Panovska-Griffiths J, Davies NG, Booy R, Eggo R. Susceptibility to and transmission of COVID-19 amongst children and adolescents compared with adults: a systematic review and meta-analysis. medRxiv. 2020. https://doi.org/10.1101/2020.05.20.20108126.

35.

Smith A, Coles S, Johnson S, Saldana L, Ihekweazu C, O’Moore É. An outbreak of influenza A (H1N1) v in a boarding school in South East England, May-June 2009. Eurosurveillance. 2009; 14(27):19263. https://doi.org/10.2807/ese.14.27.19263-en.PubMedCrossRef

36.

Cauchemez S, Ferguson NM, Wachtel C, Tegnell A, Saour G, Duncan B, Nicoll A. Closure of schools during an influenza pandemic. Lancet Infect Dis. 2009; 9(8):473–81. https://doi.org/10.1016/S1473-3099(09)70176-8.PubMedPubMedCentralCrossRef

37.

Schmidt W, Pebody R, Mangtani P. School absence data for influenza surveillance: a pilot study in the United Kingdom. Eurosurveillance. 2010; 15(3):19467. https://doi.org/10.2807/ese.15.03.19467-en.PubMedCrossRef

38.

Wichmann O, Hellenbrand W, Sagebiel D, Santibanez S, Ahlemeyer G, Vogt G, Siedler A, van Treeck U. Large measles outbreak at a German public school, 2006. Pediatr Infect Dis J. 2007; 26(9):782–6. https://doi.org/10.1097/INF.0b013e318060aca1.PubMedCrossRef

39.

Paunio M, Peltola H, Valle M, Davidkin I, Virtanen M, Heinonen OP. Explosive school-based measles outbreak: intense exposure may have resulted in high risk, even among revaccinees. Am J Epidemiol. 1998; 148(11):1103–10. https://doi.org/10.1093/oxfordjournals.aje.a009588.PubMedCrossRef

40.

Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, Massari M, Salmaso S, Tomba GS, Wallinga J, Heijne J, Sadkowska-Todys M, Rosinska M, Edmunds WJ. Social Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases. PLoS Med. 2008; 5(3):74. https://doi.org/10.1371/journal.pmed.0050074.CrossRef

41.

Prem K, Liu Y, Russell TW, Kucharski AJ, Eggo RM, Davies N, Flasche S, Clifford S, Pearson CAB, Munday JD, Abbott S, Gibbs H, Rosello A, Quilty BJ, Jombart T, Sun F, Diamond C, Gimma A, van Zandvoort K, Funk S, Jarvis CI, Edmunds WJ, Bosse NI, Hellewell J, Jit M, Klepac P. The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study. Lancet Public Heal. 2020. https://doi.org/10.1016/S2468-2667(20)30073-6.

42.

Danon L, Read JM, House TA, Vernon MC, Keeling MJ. Social encounter networks: characterizing Great Britain. Proc R Soc B Biol Sci. 2013; 280(1765):20131037. https://doi.org/10.1098/rspb.2013.1037.CrossRef

43.

Mensah AA, Sinnathamby M, Zaidi A, Coughlan L, Simmons R, Ismail SA, Ramsay ME, Saliba V, Ladhani SN. SARS-CoV-2 infections in children following the full re-opening of schools and the impact of national lockdown: Prospective, national observational cohort surveillance, July-December 2020, England. J Infect. 2021; 82(4):67–74. https://doi.org/10.1016/j.jinf.2021.02.022.PubMedPubMedCentralCrossRef

44.

Heavey L, Casey G, Kelly C, Kelly D, McDarby G. No evidence of secondary transmission of COVID-19 from children attending school in Ireland, 2020. Eurosurveillance. 2020; 25(21):2000903. https://doi.org/10.2807/1560-7917.ES.2020.25.21.2000903.PubMedCentralCrossRef

45.

Southall E, Holmes A, Hill EM, Atkins BD, Leng T, Thompson RN, Dyson L, Keeling MJ, Tildesley MJ. An analysis of school absences in England during the Covid-19 pandemic. BMC Med. 2021; 19(1):1–14. https://doi.org/10.1186/s12916-021-01990-x.CrossRef

46.

Brandal LT, Ofitserova TS, Meijerink H, Rykkvin R, Lund HM, Hungnes O, Greve-Isdahl M, Bragstad K, Nygård K, Winje BA. Minimal transmission of SARS-CoV-2 from paediatric COVID-19 cases in primary schools, Norway, August to November 2020. Eurosurveillance. 2021; 26(1):2002011. https://doi.org/10.2807/1560-7917.ES.2020.26.1.2002011.PubMedCentralCrossRef

47.

Stein-Zamir C, Abramson N, Shoob H, Libal E, Bitan M, Cardash T, Cayam R, Miskin I. A large COVID-19 outbreak in a high school 10 days after schools’ reopening, Israel, May 2020. Eurosurveillance. 2020; 25(29):2001352. https://doi.org/10.2807/1560-7917.ES.2020.25.29.2001352.PubMedCentralCrossRef

48.

Zimmerman KO, Akinboyo IC, Brookhart MA, Boutzoukas AE, McGann KA, Smith MJ, Panayotti GM, Armstrong SC, Bristow H, Parker D, et al.Incidence and secondary transmission of SARS-CoV-2 infections in schools. Pediatrics. 2021;147(4). https://doi.org/10.1542/peds.2020-048090.

49.

Molteni E, Sudre CH, Canas LS, Bhopal SS, Hughes RC, Antonelli M, Murray B, Kläser K, Kerfoot E, Chen L, et al.Illness duration and symptom profile in a large cohort of symptomatic UK school-aged children tested for SARS-CoV-2. Lancet Child Adolesc Health. 2021; 5(10):708–18. https://doi.org/10.1016/S2352-4642(21)00198-X.PubMedPubMedCentralCrossRef

50.

Chudasama DY, Tessier E, Flannagan J, Leeman D, Webster H, Demirjian A, Falconer C, Thelwall S, Kall M, Saliba V, et al.Surge in SARS-CoV-2 transmission in school-aged children and household contacts, England, August to October 2021. Eurosurveillance. 2021; 26(48):2101019. https://doi.org/10.2807/1560-7917.ES.2021.26.48.2101019.PubMedCentralCrossRef

51.

Keeling MJ, Hill EM, Gorsich EE, Penman B, Guyver-Fletcher G, Holmes A, Leng T, McKimm H, Tamborrino M, Dyson L, Tildesley MJ. Predictions of COVID-19 dynamics in the UK: Short-term forecasting and analysis of potential exit strategies. PLOS Comput Biol. 2021; 17(1):1008619. https://doi.org/10.1371/journal.pcbi.1008619.CrossRef

52.

Keeling MJ, Dyson L, Guyver-Fletcher G, Holmes A, Semple MG, Tildesley MJ, Hill EM. Fitting to the UK COVID-19 outbreak, short-term forecasts and estimating the reproductive number. Stat Methods Med Res (Special Issue: Pandemics). 2022. https://doi.org/10.1177/09622802211070257.

53.

Moore S, Hill EM, Tildesley MJ, Dyson L, Keeling MJ. Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study. Lancet Infect Dis. 2021; 21(6):793–802. https://doi.org/10.1016/S1473-3099(21)00143-2.PubMedPubMedCentralCrossRef

54.

Keeling MJ, Thomas A, Hill EM, Thompson RN, Dyson L, Tildesley MJ, Moore S. Waning, Boosting and a Path to Endemicity for SARS-CoV-2. medRxiv. 2021. https://doi.org/10.1101/2021.11.05.21265977.

55.

Moore S, Keeling MJ. Roadmaps for Relaxation of NPIs. 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/963444/S1118_Roadmaps_for_relaxation_of_NPIs__Warwick.pdf. Accessed 28 Mar 2022.

56.

Keeling MJ, Dyson L, Hill E, Moore S, Tildesley M. Road Map Scenarios and Sensitivity: Step 4. 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1001172/S1302_University_of_Warwick_Road_Map_Scenarios_and_Sensitivity_Step_4.2__6_July_2021__1_.pdf. Accessed 28 Mar 2022.

57.

Leng T, Hill EM, Holmes A, Southall E, Thompson RN, Tildesley MJ, Keeling MJ, Dyson L. Quantifying pupil-to-pupil sars-cov-2 transmission and the impact of lateral flow testing in english secondary schools. Nat Commun. 2022; 13(1):1–11. https://doi.org/10.1038/s41467-022-28731-9.CrossRef

58.

Kunzmann K, Lingjaerde C, Bird S, Richardson S. The ‘how’ matters: A simulation-based assessment of the potential contributions of LFD tests for school reopening in England. ArXiv e-prints. 2021. https://doi.org/10.48550/arXiv.2103.02035.

59.

Keeling MJ, Dyson L, Hill E, Moore S, Tildesley M. Road Map Scenarios and Sensitivity: Step 4. 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/993358/s1288_Warwick_RoadMap_Step_4.pdf. Accessed 28 Mar 2022.

60.

Keeling MJ, Dyson L, Moore S, Tildesley M, Hill E. Projections of SARS-CoV-2 transmission and COVID-19 disease until June 2022: the action of waning efficacy and boosters. 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1027907/S1384_Warwick_Autumn_and_Winter_scenarios.pdf. Accessed 28 Mar 2022.

61.

Keeling MJ, Dyson L, Tildesley MJ, Hill EM, Moore S. Comparison of the 2021 covid-19 ‘roadmap’ projections against public health data. medRxiv. 2022. https://doi.org/10.1101/2022.03.17.22272535.

62.

Dyson L, Hill EM, Moore S, Curran-Sebastian J, Tildesley MJ, Lythgoe KA, House T, Pellis L, Keeling MJ. Possible future waves of SARS-CoV-2 infection generated by variants of concern with a range of characteristics. Nat Commun. 2021; 12:5730. https://doi.org/10.1038/s41467-021-25915-7.PubMedPubMedCentralCrossRef

63.

Challen R, Dyson L, Overton CE, Guzman-Rincon LM, Hill EM, Stage HB, Brooks-Pollock E, Pellis L, Scarabel F, Pascall DJ, et al.Early epidemiological signatures of novel SARS-CoV-2 variants: establishment of B.1.617.2 in England. medRxiv. 2021. https://doi.org/10.1101/2021.06.05.21258365.

64.

Brown KA, Gubbay J, Hopkins J, Patel S, Buchan SA, Daneman N, Goneau LW. S-gene target failure as a marker of variant B.1.1.7 among SARS-CoV-2 isolates in the greater Toronto area, December 2020 to March 2021. JAMA. 2021; 325(20):2115–6. https://doi.org/10.1001/jama.2021.560710.1001/jama.2021.5607.PubMedPubMedCentralCrossRef

65.

UKHSA. COVID-19 vaccine weekly surveillance reports. 2021. https://www.gov.uk/government/publications/covid-19-vaccine-weekly-surveillance-reports#full-publication-update-history. Accessed 28 Mar 2022.

66.

Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E, Groves N, Dabrera G, et al., N Engl J Med. Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant. 2021;585–94. https://doi.org/10.1056/NEJMoa2108891.

67.

JCVI. COVID-19 vaccination of children and young people aged 12 to 17 years: JCVI statement 4th August 2021. 2021. https://www.gov.uk/government/publications/covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years-jcvi-statement. Accessed 28 Mar 2022.

68.

JCVI. COVID-19 vaccination of children and young people aged 12 to 17 years: JCVI statement 25th October 2021. 2021. https://www.gov.uk/government/publications/jcvi-statement-august-2021-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years/. Accessed 28 Mar 2022.

69.

JCVI. COVID-19 vaccination in children and young people aged 16 to 17 years: JCVI statement 15th November 2021. 2021. https://www.gov.uk/government/publications/covid-19-vaccination-in-children-and-young-people-aged-16-to-17-years-jcvi-statement-november-2021. Accessed 28 Mar 2022.

70.

JCVI. JCVI update on advice for COVID-19 vaccination of children and young people: JCVI statement 22nd December 2021. 2021. https://www.gov.uk/government/publications/jcvi-update-on-advice-for-covid-19-vaccination-of-children-and-young-people. Accessed 28 Mar 2022.

71.

JCVI. COVID-19 vaccination of children aged 12 to 15 years: JCVI statement 3rd September 2021. 2021. https://www.gov.uk/government/publications/covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years-jcvi-statement. Accessed 28 Mar 2022.

72.

JCVI. UK vaccine response to the Omicron variant: JCVI advice 29th November. 2021. https://www.gov.uk/government/publications/uk-vaccine-response-to-the-omicron-variant-jcvi-advice. Accessed 28 Mar 2022.

73.

Saadi N, Chi Y, Ghosh S, Eggo RM, McCarthy CV, Quaife M, Dawa J, Jit M, Vassall A, et al.Models of COVID-19 vaccine prioritisation: a systematic literature search and narrative review. BMC Med. 2021; 19(1):1–11. https://doi.org/10.1186/s12916-021-02190-3.CrossRef

74.

Ward JL, Harwood R, Smith C, Kenny S, Clark M, Davis PJ, Draper ES, Hargreaves D, Ladhani S, Linney M, et al.Risk factors for PICU admission and death among children and young people hospitalized with COVID-19 and PIMS-TS in England during the first pandemic year. Nat Med. 2022; 28:193–200. https://doi.org/10.1038/s41591-021-01627-9.PubMedCrossRef

75.

Szucs T. Cost–benefits of vaccination programmes. Vaccine. 2000; 18:49–51. https://doi.org/10.1016/s0264-410.CrossRef

76.

Park M, Jit M, Wu JT. Cost-benefit analysis of vaccination: a comparative analysis of eight approaches for valuing changes to mortality and morbidity risks. BMC Med. 2018; 16(1):1–11. https://doi.org/10.1186/s12916-018-1130-7.CrossRef

77.

Luyten J, Kessels R, Atkins KE, Jit M, Van Hoek AJ. Quantifying the public’s view on social value judgments in vaccine decision-making: A discrete choice experiment. Soc Sci Med. 2019; 228:181–93. https://doi.org/10.1016/j.socscimed.2019.03.025.PubMedCrossRef

78.

Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation. 2021; 144(6):471–84. https://doi.org/10.1161/CIRCULATIONAHA.121.056135.PubMedPubMedCentralCrossRef

79.

Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A. Myocarditis and pericarditis after vaccination for covid-19. JAMA. 2021; 326(12):1210–12. https://doi.org/10.1001/jama.2021.13443.PubMedPubMedCentralCrossRef

80.

Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, Loran D, Hrncir D, Herring K, Platzer M, et al.Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military. JAMA Cardiol. 2021; 6(10):1202–6. https://doi.org/10.1001/jamacardio.2021.2833.PubMedCrossRef

81.

Mouch SA, Roguin A, Hellou E, Ishai A, Shoshan U, Mahamid L, Zoabi M, Aisman M, Goldshmidt N, Yanay NB. Myocarditis following COVID-19 mRNA vaccination. Vaccine. 2021. https://doi.org/10.1016/j.vaccine.2021.05.087.

82.

Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, Nordvig AS, Shalev D, Sehrawat TS, et al.Post-acute COVID-19 syndrome. Nat Med. 2021; 27(4):601–15. https://doi.org/10.1038/s41591-021-01283-z.PubMedPubMedCentralCrossRef

83.

Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, Villapol S. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. Scientific Reports. 2021; 11:16144. https://doi.org/10.1038/s41598-021-95565-8.PubMedPubMedCentralCrossRef

Title: An assessment of the vaccination of school-aged children in England against SARS-CoV-2
Authors: Matt J. Keeling
Sam E. Moore
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Vaccination
SARS-CoV-2
Published in: BMC Medicine / Issue 1/2022
Electronic ISSN: 1741-7015
DOI: https://doi.org/10.1186/s12916-022-02379-0

At a glance: The STEP trials

Springer Medicine

An assessment of the vaccination of school-aged children in England against SARS-CoV-2

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

The need for screening, early diagnosis, and prediction of chronic kidney disease in people with diabetes in low- and middle-income countries—a review of the current literature

International surveillance study in acute spinal cord injury confirms viability of multinational clinical trials

Homelessness and health-related outcomes: an umbrella review of observational studies and randomized controlled trials

Identifying and ranking causal biochemical biomarkers for breast cancer: a Mendelian randomisation study

Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial

Identification of heart failure with preserved ejection fraction helps risk stratification for hypertrophic cardiomyopathy